Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

 

 

Mitomycin C,50-07-7
Mitomycin C
Mitomycin C,50-07-7
CAS
50-07-7
Molecular Formula
C15H18N4O5
Molecular Weight
334.33
Systematic Name
Mitomycin
Assay
USP35
Certificate of analysis
Mitomycin C,50-07-7
View via PDF file
Mitomycin C,50-07-7
Specification
Items
Specification
Test result
Appearance
Deep blue purple crystalline powder
Complies
Identification
A: Ultraviolet absorption:absorptivity at 357nm is
not less than 95.0% and not more
than 105.0%
Complies
B: IR spectrum exhibits maxima only at the same
wavelengths as that of a similar preparation of the
reference standard
Complies
C: The principal peak in chromatogram obtained
with the test solution is similar in retention time and
size to the principal peak
in the chromatogram obtained with the reference solution
Complies
Solubility
Slightly soluble in water, soluble in acetone ,in
methanol, in butyl acetate, and in cyclohexanone
Complies
Crystallinity
Meets the requirements
Complies
Water
<2.5%
0.2%
pH
6.0 - 7.5
6.47
Acetone
<5000ppm
410ppm
Methanol
<3000ppm
790ppm
Ethyl Ether
<5000ppm
230ppm
Residue on ignition
<0.1%
0.06%
Heavy metals
<0.003%
Complies
Assay
>970ug/mg
985ug/mg
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Mitomycin C,50-07-7
Packing 1
1g
Packing 2
10g
   
   
   
Bulk request
sales@lanospharma.com
Related Antineoplastic Antibiotics
   
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Mitomycin C,50-07-7).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.